Tanya Simuni1, Chelsea Caspell-Garcia2, Christopher Coffey2, Lama M Chahine3, Shirley Lasch4, Wolfgang H Oertel5, Geert Mayer6, Birgit Högl7, Ron Postuma8, Aleksandar Videnovic9, Amy Willis Amara10, Ken Marek4. 1. Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2. The University of Iowa, Iowa City, IA, USA. 3. The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 4. Institute for Neurodegenerative Disorders, New Haven, CT, USA. 5. Charitable Hertie Foundation, Frankfurt/Main, Germany. 6. Hephata-Klinik, Hephata Hessisches Diakoniezentrum e. V. 7. Innsbruck Medical University, Innsbruck, Austria. 8. McGill University, Montréal, Québec, Canada. 9. Massachusetts General Hospital, Boston, MA, USA. 10. UAB School of Medicine, Birmingham, AL, USA.
Abstract
OBJECTIVE: This study was undertaken to determine the frequency and correlates of excessive daytime sleepiness in de novo, untreated Parkinson's disease (PD) patients compared with the matched healthy controls. METHODS: Data were obtained from the Parkinson's Progression Markers Initiative, an international study of de novo, untreated PD patients and healthy controls. At baseline, participants were assessed with a wide range of motor and nonmotor scales, including the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Excessive daytime sleepiness was assessed based on the Epworth Sleepiness scale (ESS), with a cutoff of 10. RESULTS: Four hundred twenty-three PD subjects and 196 healthy controls were recruited into the study. Mean ESS (min, max) score was 5.8 (0, 20) for the PD subjects and 5.6 (0, 19) for healthy controls (P = 0.54). Sixty-six (15.6%) PD subjects and 24 (12%) healthy controls had ESS of at least 10 (P = 0.28). No difference was seen in demographic characteristics, age of onset, disease duration, PD subtype, cognitive status, or utilization of sedatives between the PD sleepiness-positive versus the negative group. The sleepiness-positive group had higher MDS-UPDRS Part I and II but not III scores, and higher depression and autonomic dysfunction scores. Sleepiness was associated with a marginal reduction of A-beta (P = 0.05) but not alpha-synuclein spinal fluid levels in PD. CONCLUSIONS: This largest case control study demonstrates no difference in prevalence of excessive sleepiness in subjects with de novo untreated PD compared with healthy controls. The only clinical correlates of sleepiness were mood and autonomic dysfunction. Ongoing longitudinal analyses will be essential to further examine clinical and biological correlates of sleepiness in PD and specifically the role of dopaminergic therapy.
OBJECTIVE: This study was undertaken to determine the frequency and correlates of excessive daytime sleepiness in de novo, untreated Parkinson's disease (PD) patients compared with the matched healthy controls. METHODS: Data were obtained from the Parkinson's Progression Markers Initiative, an international study of de novo, untreated PDpatients and healthy controls. At baseline, participants were assessed with a wide range of motor and nonmotor scales, including the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Excessive daytime sleepiness was assessed based on the Epworth Sleepiness scale (ESS), with a cutoff of 10. RESULTS: Four hundred twenty-three PD subjects and 196 healthy controls were recruited into the study. Mean ESS (min, max) score was 5.8 (0, 20) for the PD subjects and 5.6 (0, 19) for healthy controls (P = 0.54). Sixty-six (15.6%) PD subjects and 24 (12%) healthy controls had ESS of at least 10 (P = 0.28). No difference was seen in demographic characteristics, age of onset, disease duration, PD subtype, cognitive status, or utilization of sedatives between the PD sleepiness-positive versus the negative group. The sleepiness-positive group had higher MDS-UPDRS Part I and II but not III scores, and higher depression and autonomic dysfunction scores. Sleepiness was associated with a marginal reduction of A-beta (P = 0.05) but not alpha-synuclein spinal fluid levels in PD. CONCLUSIONS: This largest case control study demonstrates no difference in prevalence of excessive sleepiness in subjects with de novo untreated PD compared with healthy controls. The only clinical correlates of sleepiness were mood and autonomic dysfunction. Ongoing longitudinal analyses will be essential to further examine clinical and biological correlates of sleepiness in PD and specifically the role of dopaminergic therapy.
Authors: Jitka Bušková; Jiří Klempíř; Veronika Majerová; Jana Picmausová; Karel Sonka; Robert Jech; Jan Roth; Evžen Růžička Journal: J Neurol Date: 2011-06-03 Impact factor: 4.849
Authors: Min Shi; Joshua Bradner; Aneeka M Hancock; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; Hojoong M Kim; James B Leverenz; Thomas J Montine; Carmen Ginghina; Un Jung Kang; Kevin C Cain; Yu Wang; Jan Aasly; David Goldstein; Jing Zhang Journal: Ann Neurol Date: 2011-03-11 Impact factor: 10.422
Authors: C Rodriguez-Blazquez; M J Forjaz; B Frades-Payo; J de Pedro-Cuesta; P Martinez-Martin Journal: Eur J Neurol Date: 2009-09-23 Impact factor: 6.089
Authors: David R Shprecher; Charles H Adler; Nan Zhang; Holly A Shill; Christine M Belden; Erika Driver-Dunckley; Shyamal H Mehta; Kathryn J Davis; Lucia I Sue; Edward Zamrini; Thomas G Beach Journal: Clin Neurol Neurosurg Date: 2020-02-06 Impact factor: 1.876
Authors: Amy W Amara; Lama M Chahine; Chelsea Caspell-Garcia; Jeffrey D Long; Christopher Coffey; Birgit Högl; Aleksandar Videnovic; Alex Iranzo; Geert Mayer; Nancy Foldvary-Schaefer; Ron Postuma; Wolfgang Oertel; Shirley Lasch; Ken Marek; Tanya Simuni Journal: J Neurol Neurosurg Psychiatry Date: 2017-05-29 Impact factor: 10.154
Authors: Gennaro Pagano; Sophie Molloy; Peter G Bain; Eugenii A Rabiner; K Ray Chaudhuri; David J Brooks; Nicola Pavese Journal: Neurology Date: 2016-11-02 Impact factor: 9.910